The recommended starting dose is 5 mg twice daily, given orally.¹

Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs that cannot be managed by concomitant medicinal products or dose adjustments.

If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.

INLYTA® is available in 1 mg, 3 mg, 5 mg and 7 mg film-coated tablets to help dose adjustment.¹

The dose of INLYTA® can be titrated: increased in the absence of adverse events (AEs) or decreased in the presence of AEs.¹

Patients who tolerate the starting dose of 5 mg twice daily with no adverse reactions >grade 2 for 2 consecutive weeks may have their dose increased to 7 mg twice daily unless the patient's blood pressure is >150/90 mmHg, or the patient is receiving antihypertensive treatment.¹

​​Subsequently, using the same criteria, patients who tolerate a dose of 7 mg twice daily may have their dose increased to a maximum of 10 mg twice daily.¹

Conversely, if adverse reactions develop, the dose may be reduced to 3 mg twice daily and then to 2 mg twice daily if needed.¹

^†If a strong CYP3A4/5 inhibitor must be co-administered, a dose decrease from 5 mg BID to 2 mg BID is recommended. If a strong CYP3A4/5 inducer must be co-administered, a gradual dose increase is recommended and patients should be monitored for toxicities.¹ However, it is preferable to select alternative medicines with no or minimal interaction potential as these dose adjustments have not been studied in patients receiving strong CYP3A4/5 inhibitors or inducers.

The half-life of INLYTA® is between 2.5 and 6.1 hours¹

A short half-life could potentially lead to a relatively quick resolution of

some adverse reactions following a temporary treatment break (discontinuation) of 2 to 3 days.²
 

Once any adverse reactions subside, treatment with INLYTA® can be

restarted, if necessary at a reduced dose.²